Literature DB >> 1850442

Mechanisms of fluoroquinolone resistance in Staphylococcus aureus.

G W Kaatz1, S M Seo, C A Ruble.   

Abstract

Fluoroquinolone resistance that arose in the test strain during ciprofloxacin therapy of experimental Staphylococcus aureus endocarditis was studied. In two isolates, resistance was due to a decreased sensitivity of the process of DNA synthesis to fluoroquinolones, suggesting the presence of an altered DNA gyrase. Another isolate had an enhanced energy-dependent mechanism, possibly an efflux system, by which cell-associated [3H]norfloxacin was reduced. When a 2.7-kb SphI-KpnI chromosomal fragment from this organism was cloned into pUC19, fluoroquinolone resistance was expressed in an Escherichia coli host, and such organisms acquired an energy-dependent ability to reduce cell-associated [3H]norfloxacin. Lack of homology between this DNA and other cloned gyrA genes indicated that its protein products are distinct from the gyrA protein. S. aureus has the capability of decreasing the quantity of cell-associated fluoroquinolone. An enhancement of this system by an as yet undefined mechanism and an alteration in DNA gyrase are two means by which this organism can develop resistance to fluoroquinolones.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1850442     DOI: 10.1093/infdis/163.5.1080

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  51 in total

Review 1.  Efflux-mediated resistance to fluoroquinolones in gram-positive bacteria and the mycobacteria.

Authors:  K Poole
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

2.  Detection of gyrA gene mutations associated with ciprofloxacin resistance in methicillin-resistant Staphylococcus aureus: analysis by polymerase chain reaction and automated direct DNA sequencing.

Authors:  J J Goswitz; K E Willard; C E Fasching; L R Peterson
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

Review 3.  Active efflux mechanisms for antimicrobial resistance.

Authors:  S B Levy
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

Review 4.  Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A N Wadworth; K L Goa
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

5.  In vitro activities of ciprofloxacin and rifampin alone and in combination against growing and nongrowing strains of methicillin-susceptible and methicillin-resistant Staphylococcus aureus.

Authors:  D Bahl; D A Miller; I Leviton; P Gialanella; M J Wolin; W Liu; R Perkins; M H Miller
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

6.  Analyses of multidrug efflux pump-like proteins encoded on the Staphylococcus aureus chromosome.

Authors:  Bryan D Schindler; Emmanuel Frempong-Manso; Carmen E DeMarco; Christos Kosmidis; Varun Matta; Susan M Seo; Glenn W Kaatz
Journal:  Antimicrob Agents Chemother       Date:  2014-11-17       Impact factor: 5.191

7.  In vitro activity of the new fluoroquinolone CP-99,219.

Authors:  H C Neu; N X Chin
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

Review 8.  Mechanisms of resistance to quinolones.

Authors:  E Cambau; L Gutmann
Journal:  Drugs       Date:  1993       Impact factor: 9.546

9.  Hydrophilicity of quinolones is not an exclusive factor for decreased activity in efflux-mediated resistant mutants of Staphylococcus aureus.

Authors:  T Takenouchi; F Tabata; Y Iwata; H Hanzawa; M Sugawara; S Ohya
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

10.  Ciprofloxacin-induced, low-level resistance to structurally unrelated antibiotics in Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus.

Authors:  J Fung-Tomc; B Kolek; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.